

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



PCT

(43) International Publication Date
13 April 2006 (13.04.2006)

(10) International Publication Number
WO 2006/037247 A1

(51) International Patent Classification:
A61K 39/395 (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/CH2005/000566

(22) International Filing Date:
30 September 2005 (30.09.2005)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
04405628.1 7 October 2004 (07.10.2004) EP

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): UNIVERSITÄT ZÜRICH [CH/CH]; Prorektorat Forschung, Rämistrasse 71, CH-8006 Zürich (CH).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and
(75) Inventors/Applicants (for US only): GILLIET, Michel [CH/US]; 3703 Abbeywood Drive, 77584 Pearland (US). NESTLE, Frank, O. [DE/US]; 420 East 61st Street, 10021 New York (US).
(74) Agent: SCHMAUDER & PARTNER AG; Zwängiweg 7, CH-8038 Zürich (CH).

WO 2006/037247 A1

(54) Title: TYPE I INTERFERON BLOCKING AGENTS FOR PREVENTION AND TREATMENT OF PSORIASIS

(57) Abstract: The discovery of plasmacytoid dendritic cell precursors (PDC) as crucial effector cells with high production of type I interferons (IFNs) in early psoriasis development has led to the present invention that blocking of type I IFNs can be used for prevention and therapy of psoriasis. The invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist (e.g. an anti-IFN- α antibody) or type I IFN receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.

Type I interferon blocking agents for prevention and treatment of psoriasis

Field of the invention

5

The invention relates to the use of a type I interferon blocking agent for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.

10 Background of the invention

Psoriasis is a common autoimmune-related inflammatory disease affecting the human skin. There is compelling evidence that, similarly to Crohn's disease and rheumatoid arthritis, psoriasis formation results from an overt self-perpetuating activation of

15 autoreactive IFN- γ secreting T cells. The initial onset of skin lesions is followed by chronic relapses of the disease, typically triggered by environmental factors including infections, mechanical stress and drugs. It has been proposed that these insults may drive the pathogenic T cell cascade through a yet unidentified innate immune response.

20 Plasmacytoid dendritic cell precursors (PDC) are key effectors in innate antiviral immunity due to their unique ability to secrete large amounts of type I interferons (IFN- α/β) in response to viral stimulation. Virally exposed PDC subsequently differentiate into T cell stimulatory dendritic cells (DC) themselves or induce maturation of bystander myeloid DC through IFN- α , thus providing a unique link between innate and adaptive anti-viral immunity. During homeostasis, PDC are encountered exclusively in blood and lymphoid organs, however viral infection leads to active recruitment of PDC from the blood into peripheral sites of primary infection. Wollenberg et al. [J Invest Dermatol 2002, 119: 1096-25 102] have shown that PDC may also accumulate in peripheral tissues of certain non-infectious inflammatory disorders such as allergic contact dermatitis, cutaneous lupus erythematosus and psoriasis, however a functional relevance for PDC or their secreted products such as type I IFNs has not been addressed or proven so far.

30 Type I (IFN- α , IFN- β , IFN- ω) IFNs are members of a cytokine family including several structurally related IFN- α proteins and a single IFN- β protein binding to the type I IFN

35 surface receptor. Type I IFNs inhibit viral replication, increase the lytic potential of NK

cells, increase expression of class I MHC molecules and stimulate the development of T helper 1 cells in humans.

In the past, there have been some reports in the literature dealing with the association 5 between psoriasis and type I IFNs or the description of IFN- α blocking agents. Schmid et al. [J of IFN Res 1994, 14: 229-234] have detected low levels of IFN- α mRNA expression in psoriasis epidermis. However, they failed to show IFN- α expression on the protein level. Furthermore IFN- α was found only in the epidermal compartment. Although the authors provided direct evidence that the IFN- α system is locally activated in psoriasis they 10 concluded that this might be the result of a viral infection or a dysregulation of the cytokine network.

Van der Fits et al. [J Invest Dermatol 2004, 122: 51-60] describe an activated type I 15 interferon signalling pathway in psoriatic lesional skin, but do not suggest that blocking of this pathway could be used for prevention or therapy of psoriasis. Single case reports have indicated that systemic IFN- α given during adjuvant therapy of melanoma or hepatitis therapy can occasionally trigger psoriasis in predisposed individuals [Pauluzzi et al., Acta Derm Venereol 1993, 73: 395; Funk et al., Br J Dermatol 1991, 125: 463-5]. 20 However, this is a rare event considering the high prevalence of psoriasis and the frequent use of IFN- α in cancer patients as well as in anti-infectious therapy. Furthermore, IFN- α is just thought of being one of many factors able to induce psoriasis. Other factors such as physical and psychological stress, HIV infection as well as various medications including lithium, beta blockers and anti-malarial drugs are also well-known triggers of 25 psoriasis. Therapeutic IFN- α doses, added through the exogenous route, might be a non-specific trigger of several possible downstream psoriasis inducing factors.

Chunthrapai et al. [Cytokine 2001, 15: 250-260] focus on the development of a 30 therapeutic agent that neutralizes IFN- α , i.e. the development of a humanized antibody. No experimental data are provided to show prevention or therapy in any of the known autoimmune diseases, although insulin-dependent diabetes mellitus (IDDM) or systemic lupus erythematosus (SLE) are mentioned as potential diseases to be treated. The paper questions the statement about an association between IFN- α and psoriasis or Crohn's disease by referring to the limited number of patients having been analyzed.

35 WO 00/64936 [Wieser] describes peptide homodimers and peptide heterodimers binding to the IFN- α 2 receptor and focuses on the physical and biochemical activities of these

compounds representing IFN- α 2 substitutes. Application of these compounds to inflammatory and neoplastic diseases in the broadest sense are suggested, and the list of diseases also contains psoriasis. However, there is no indication that IFN- α 2 antagonists should be used.

5

There is an unmet need for novel psoriasis therapies since current therapies of psoriasis are limited by their limited efficacy, their side effects and their inability to prevent new relapses. While novel drugs such as anti-TNF- α targeted therapies are able to induce fast disease remission, long term therapy is not an option due to their high potential toxicity.

10

Summary of the invention

The invention relates to the use of a type I interferon blocking agent, such as a type I IFN antagonist or type I IFN-receptor antagonist, for the preparation of a medicament for the prevention and treatment of psoriasis, and to a method of prevention and treatment of psoriasis using a type I interferon blocking agent.

In particular, the invention relates to such a use, wherein the type I IFN antagonist is an IFN- α antagonist, for example an anti-IFN- α antibody or antibody fragment, preferably a humanized antibody, a type I IFN receptor fusion protein, or also short interfering (si) RNA or antisense oligonucleotides inhibiting IFN- α production by sequence-specific targeting of IFN- α mRNA. Similar reagents antagonizing other type I IFN family members or groups of type I IFNs are also part of the invention. The invention further relates to such a use, wherein the type I IFN-receptor antagonist is an anti-IFN- α/β -receptor antibody or antibody fragment, mutant type I IFN/Fc fusion protein or small molecule specifically interfering with type I IFN signalling.

Brief description of the figures

30 **Figure 1.** *IFN- α production is an early event during the development of psoriatic skin lesions and is principally mediated by dermal PDC.*

(a) Normalized IFN- α and IRF-7 mRNA expression in psoriatic plaque lesions (PP, n=24) and normal skin (NN, n=11). The figures of the x axis (mRNA) represent relative mRNA expression.

35 (b) Immunohistochemistry for MxA protein on cryosections of psoriatic plaque lesions (PP, n=8), uninvolved skin of psoriatic patients (PN, n=4), normal skin of healthy individuals

(NN, n=4) and atopic dermatitis skin (AD, n=4) specimen. Percentages of MxA-positive cells among the total dermal and epidermal cells are calculated from mean of two independent counts of three random fields with a 400-fold magnification. + = 0-25%, ++ = 25-50%, +++ = 50-75%, ++++ = 75-100%, < = below detection limit.

5 (c) Lesional IFN- α expression during the spontaneous development of a psoriatic lesion from uninvolved skin transplanted onto AGR^{-/-} mice. Kinetics of human IFN- α mRNA expression relative to human GAPDH mRNA (IFN- α mRNA, bars) in comparison to the expansion of resident CD3 T cells (CD3, solid line) and the induction of psoriatic papillomatosis (Pap, dashed line). d=days after transplantation. Data represent the mean
10 +/- standard deviation (SD) of two independent experiments.

(d) Double staining of intracellular IFN- α and surface BDCA-2 in dermal single cell suspensions derived from developing psoriatic lesions (d-PP, advancing edges of a psoriatic plaques) and uninvolved skin (PN). Figures in the quadrants represent %.

15 **Figure 2.** *IFN- α / β signalling is crucial for local T cell expansion and the development of psoriasis.*

(a) Total CD3 T cell count and (b) epidermal papillomatosis (Pap) in skin grafts before transplantation (uninvolved skin day 0, PN) and 35 days post transplantation (p.t.) following the administration of isotype-matched control antibody (IgG) or an anti-IFN- α / β -receptor mAb (α -IFN-R), or in a psoriatic plaque (PP) of the graft donor. Error bars in (a) represent one standard deviation (SD). Dots in (b) represent independently grafted mice.

Figure 3. *The development of psoriasis is dependent on type I IFN production by PDC.*

(a) Total human IFN- α mRNA expression relative to human GAPDH mRNA in skin grafts harvested 13 days post transplantation (p.t.) following the administration of isotype-control Ab (IgG) or anti-BDCA-2 mAb (α -BDCA-2).

(b) Total CD3 T cell count, (c) epidermal papillomatosis (Pap) and (d) acanthosis (Ac) in skin grafts before transplantation (uninvolved skin d 0, PN) and 35 days post transplantation (p.t.) following the administration of isotype-matched control Ab (IgG), anti-BDCA-2 mAb (α -BDCA-2), or anti-BDCA2 plus human recombinant IFN- α 2 (α -BDCA-2 + IFN- α).

Detailed description of the invention

35 The discovery of PDC as crucial effector cells with high production of type I IFNs in early psoriasis development has led to the present invention that blocking of type I IFNs can be

used as prevention and therapy of psoriasis. High numbers of PDC infiltrating the skin of both psoriatic plaque lesions as well as uninvolved (normal appearing) skin of psoriatic patients can be shown by immunohistochemistry and flow cytometry of single cell suspensions using an antibody specific for PDC (anti-BDCA-2). Interestingly, in contrast to the resting phenotype of PDC in uninvolved skin, PDC infiltrating psoriatic plaque lesions display an activated phenotype. PDC activation during the transition from uninvolved skin into psoriatic plaque lesions contributes to the pathogenesis of psoriasis.

Antagonizing type I IFNs (e.g. antagonizing IFN- α , while leaving IFN- β intact) provides the unique opportunity to specifically target the type I IFN mediated autoimmune disease process in psoriasis while potentially leaving an important IFN- β mediated antiviral immune response intact. Antagonizing IFN- α not only clears the disease, but also prevents relapse as is demonstrated in a relevant preclinical model. The AGR psoriasis mouse model [Boyman et al., J Exp Med 2004, 199: 731-736] provides for the first time the platform to prove the effectiveness of type I IFN blocking in prevention and therapy of psoriasis. This clinically relevant psoriasis model supports that inhibiting type I IFN blocks development of psoriasis and is a potent way to prevent and treat psoriasis in humans.

IFN- α expression during the development of psoriatic lesions is studied in a xenotransplantation model, in which uninvolved skin of psoriatic patients transplanted onto AGR^{-/-} mice spontaneously converts into a fully-fledged psoriatic skin lesion within 35 days. AGR129 mice, deficient in type I (A) and type II (G) IFN receptor in addition to being RAG-^{-/-}, are kept pathogen-free throughout the study. Keratomes of uninvolved skin are transplanted to the back of mice using an absorbable tissue seal. This humanized mouse model system is dependent on the local activation and proliferation of resident human T cells derived from the engrafted pre-psoriatic skin.

Initial screening of psoriatic plaque lesions does not show significant upregulation of IFN- α mRNA compared to normal skin of healthy donors. However, psoriatic plaque lesions but not uninvolved skin or normal skin demonstrate an IFN- α signature with significantly increased expression of IRF-7, an IFN- α inducible gene (Fig. 1a), and the presence of the IFN- α inducible MxA protein (Fig. 1b), suggesting that IFN- α is produced earlier during the development of the psoriatic phenotype. Analysis of human IFN- α expression reveals increased mRNA levels as early as day 7 after engraftment, reaching a peak at day 14, before rapidly declining (Fig. 1c). The induction of IFN- α expression at day 7 and 14 is paralleled by the local expansion of resident T cells. In contrast, disease formation,

quantified by epidermal papillomatosis, shows delayed kinetics, starting at day 21 after transplantation and reaching its full development at day 35 (Fig. 1c). These data indicate that IFN- α expression is especially important during the early phase of the development of the psoriatic phenotype but has consequences for the whole disease process.

5

Intracellular IFN- α expression is confined to BDCA2 $+$ cells (Fig. 1d), indicating that PDC represent the principal IFN- α producers in developing psoriatic skin lesions. By contrast, IFN- α expression is not detectable on PDC derived from uninvolved skin nor in peripheral blood of the same psoriasis patient. Since PDCs contain high amounts of type I

10 interferons, PDC-derived IFN- α plays a crucial role in the elicitation of psoriasis.

Intravenous injection of neutralizing anti-IFN- α / β -receptor antibody, starting immediately after transplantation, inhibits the local activation and expansion of resident T cells (Fig. 2a), and completely blocks the development of the psoriatic phenotype, with a significant 15 reduced papillomatosis (Fig. 2b) compared to mice receiving the isotype-matched control antibody.

The spontaneous conversion of uninvolved pre-psoriatic skin to psoriasis in AGR $^{-/-}$ mice is mediated by PDC activation and the secretion of IFN- α . Anti-BDCA2 antibody specifically 20 targets human PDC and inhibits type I IFN-production by PDC *in vitro*. Intravenous injection of anti-BDCA2 monoclonal antibody (mAb) leads to a 14-fold reduction of lesional IFN- α at day 13 after transplantation (Fig. 3a), inhibits the dermal T cell expansion (Fig. 3b) and the development of the psoriasis phenotype, quantified by epidermal papillomatosis (Fig. 3c) and acanthosis (Fig. 3d).

25

Addition of exogenous IFN- α to the PDC-blocking by anti-BDCA2 treatment completely reverses the inhibition of T cell expansion (Fig. 3b) and induction of psoriasis development (Fig. 3c, d), confirming that the development of psoriasis is mediated by IFN- α production by PDC. These data prove that IFN- α is the responsible type IFN for psoriasis 30 development.

Specific blockade of IFN- α blocks psoriasis while leaving IFN- β signalling intact for a potential antiviral immune response.

35

Blocking agents refer to any DNA, RNA (si RNA, antisense molecules), peptide, protein (including fusion protein), antibody or small molecules interfering with type I IFN signalling

and function and/or type I IFN production by PDCs in inflammatory diseases. In particular such blocking agents are (i) humanized or human anti-IFN- α whole antibodies or antibody fragments (Fab or scFv), antagonizing secreted IFN- α , (ii) short interfering (si) RNA or antisense oligonucleotides inhibiting IFN- α production, (iii) anti-IFN- α / β -receptor antibodies, mutant type I IFN/Fc fusion proteins, type I IFN receptor fusion proteins, or small molecules interfering with type I IFN signalling.

One aspect of the invention relates to a method of treating psoriasis comprising administering an anti-IFN- α antibody or antibody fragment in a quantity effective against psoriasis to a mammal in need thereof, for example to a human requiring such treatment. The treatment may be for prophylactic or therapeutic purposes. For the administration, the anti-IFN- α antibody is preferably in the form of a pharmaceutical preparation comprising the anti-IFN- α antibody and optionally a pharmaceutically acceptable carrier and optionally adjuvants. The anti-IFN- α antibody is used in an amount effective against psoriasis. The dosage of the active ingredient depends upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, the mode of administration, and whether the administration is for prophylactic or therapeutic purposes. In the case of an individual having a bodyweight of about 70 kg the daily dose administered is from approximately 1 mg to approximately 500 mg, preferably from approximately 10 mg to approximately 100 mg, of an anti-IFN- α antibody.

Administering other blocking agents referred to above is also included in the invention, in particular administering pharmaceutical preparations comprising short interfering (si) RNA or antisense oligonucleotides inhibiting IFN- α production, or anti-IFN- α / β -receptor antibodies, mutant type I IFN/Fc fusion proteins, type I IFN receptor fusion proteins or small molecules interfering with type I IFN signalling. These compounds are likewise used in an amount effective against psoriasis. The dosage is chosen by the practitioner based on the particular compound to be administrated and the individual pharmacokinetic data, and also on the species, its age, weight, and individual condition and the mode of administration.

Pharmaceutical compositions for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, are especially preferred. The pharmaceutical compositions comprise from approximately 1% to approximately 95% active ingredient, preferably from approximately 20% to approximately 90% active ingredient.

For parenteral administration preference is given to the use of suspensions or dispersions of the anti-IFN- α antibody or other type I IFN blocking agent mentioned above, especially in isotonic aqueous solutions, which, for example, can be made up shortly before use. The

5 pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, viscosity-increasing agents, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known *per se*, for example by means of conventional dissolving and lyophilizing processes.

10

An antibody useful in the invention is prepared by standard methods. Humanized antibodies and antibody fragments are obtained by recombinant technologies as previously described [reviewed by Dall'Acqua et al., *Curr Op Struct Biol* 1988, 8: 443-50].

Alternatively, entirely human antibodies can be obtained using either phage display

15

technologies [reviewed by Winter et al., *Annu Rev Immunol* 1994, 12: 433-55] or transgenic "human" mice with partial human heavy and light chain loci inserted into their genomes [reviewed by Brüggeman et al., *Curr Op Biotechnol* 1997, 8: 503-8]. Preparation of si RNA or antisense oligonucleotides likewise uses standard technology.

20

An anti-IFN- α antibody or other type I IFN blocking agent mentioned above can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations of a blocking agent of the invention and one or more other therapeutic agents known in the treatment of psoriasis, the administration being staggered or given independently of one another, or being in the

25

form of a fixed combination.

Combination partners considered are topical corticosteroids, UV light, retinoids, methotrexate, other biologics targeting the altered immune system in psoriasis or derivatives of vitamin D3.

30

The following Examples serve to illustrate the invention without limiting the invention in its scope.

Examples

35

Real time quantitative PCR. Total RNA from homogenized skin specimens is extracted and reverse transcribed as previously described [Boyman et al., J Exp Med 2004, 199: 731-736]. Complementary DNA is quantitatively analyzed for the expression of IFN- α and IRF-7 transcripts by real time PCR, using primers designed against most human IFN- α sequences (purchased from Applied Biosystems, Foster City, CA) and against human IRF-7 (left, TCCCCACGCTATACCATCTACCT-3'; right, ACAGCCAGGGTCCAGCTT-3'). 18S ribosomal RNA is used for normalisation. In the humanized mouse model IFN- α quantification is done by using a primer kit recognizing most human IFN- α genes and which does not recognize its mouse counterpart (purchased from Search-LC, Heidelberg, Germany). Human GAPDH mRNA levels are quantified using human-specific primers (left, ATTGCCCTCAACGACCACTTG-3'; right, TTGATGGTACATGAAAGGTGAGG-3') and used for normalization.

Animals, and Transplantation Procedure. AGR129 mice, deficient in type I (A) and type II (G) IFN receptors in addition to being RAG-2 $^{-/-}$, are kept pathogen free throughout the study. Keratomes of symptomless pre-psoriatic skin are transplanted to the back of mice using an absorbable tissue seal, as previously described [Boyman et al., *loc. cit.*]. 35 days after engraftment transplanted skin is removed and snap frozen for histological or mRNA expression analysis. CD3+ T cell counts, acanthosis and papillomatosis index are determined histologically as previously published [Boyman et al., *loc. cit.*]. CD3+ T cell values represent the mean cell count of three random fields assessed by a 400-fold magnification by two independent investigators. The indicated papillomatosis and acanthosis values represent the mean of 10 random areas of each sample.

Neutralization Studies. Dosage and schedule of antibody administration are deduced based on previous data with anti-human monoclonal antibodies against other cell surface molecules, and administered as follows: (i) intravenous injection of 30 μ g neutralizing anti-human IFN- α/β Receptor Chain 2 (CD118) mAb (Clone MMHAR-2, purchased from PBL Biomedical Laboratories) twice weekly for 35 days, starting at day 0 after transplantation; (ii) intravenous injection of 30 μ g anti-BDCA-2 mAb (Miltenyi Biotech) twice weekly for 35 days, starting at day 0 after transplantation. For IFN- α reconstitution experiments, 30'000 IU recombinant human IFN- α 2a (Roferon $^{\circledR}$ A, Roche Pharma AG, Reinach, Switzerland) are administered subcutaneously 3 times a week for 35 days. Dosage corresponds to the therapeutic dose of 8 Mio IU used in humans, and is deduced by an allometric approach as previously described [Boyman et al., *loc. cit.*].

Claims

1. Use of a type I interferon blocking agent for the preparation of a medicament for the prevention and treatment of psoriasis.

5

2. Use according to claim 1 wherein the type I interferon blocking agent is a type I interferon antagonist.

10

3. Use according to claim 2 wherein the type I interferon antagonist is an IFN- α antagonist.

4. Use according to claim 3 wherein the IFN- α antagonist is an anti-IFN- α antibody or antibody fragment.

15

5. Use according to claim 1 wherein the type I interferon blocking agent is a type I interferon receptor fusion protein

6. Use according to claim 1 wherein the type I interferon blocking agent is a short interfering (si) RNA or an antisense oligonucleotide inhibiting IFN- α production.

20

7. Use according to claim 1 wherein the type I interferon blocking agent is a type I interferon receptor antagonist.

25

8. Use according to claim 7 wherein the type I interferon receptor antagonist is an anti-IFN- α/β -receptor antibody, mutant type I IFN/Fc fusion protein or small molecule specifically interfering with type I IFN signalling.

9. Use according to claim 7 wherein the type I interferon receptor antagonist is an anti-IFN- α/β -receptor antibody or antibody fragment.

30

10. Use according to claim 4 or 9 wherein the antibody is a humanized antibody.

11. A method of prevention and treatment of psoriasis using a type I interferon blocking agent.

35

SEQUENCE LISTING

<110> Nestle, Frank O.
Gilliet, Michel

<120> Type I interferon blocking agents for prevention and treatment of
psoriasis

<130> UZ-06/167

<160> 4

<170> PatentIn version 3.3

<210> 1
<211> 23
<212> DNA
<213> artificial

<220>
<223> primer for IRF-7, left

<400> 1
tccccacgct ataccatcta cct 23

<210> 2
<211> 19
<212> DNA
<213> artificial

<220>
<223> primer for IRF-7, right

<400> 2
acagccaggg ttccagctt 19

<210> 3
<211> 22
<212> DNA
<213> artificial

<220>
<223> primer for GAPDH, left

<400> 3
attgccctca acgaccactt tg 22


<210> 4
<211> 23
<212> DNA
<213> artificial

<220>
<223> primer for GAPDH, right


<400> 4
ttgatggtagtac atgaaaggtg agg 23

Fig. 1



(a)



(b)



(c)



(d)





Fig. 2

(a)



(b)






Fig. 3


(a)




(b)



(c)



(d)



INTERNATIONAL SEARCH REPORT

PCT/CH2005/000566

A. CLASSIFICATION OF SUBJECT MATTER
A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2004/067888 A1 (TOVEY MICHAEL GERARD ET AL) 8 April 2004 (2004-04-08) paragraph '0023!; claim 7 ----- US 2003/147889 A1 (TOVEY MICHAEL GERARD) 7 August 2003 (2003-08-07) paragraph '0024!; claim 7 ----- WO 01/54721 A (PHARMA PACIFIC PTY LTD; TOVEY, MICHAEL, GERARD) 2 August 2001 (2001-08-02) page 7, line 24; claim 7 ----- WO 98/28001 A (ADVANCED BIOTHERAPY CONCEPTS, INC) 2 July 1998 (1998-07-02) claim 39 ----- -/-	1-3,7,11 1-4,7-9, 11 1-4,11 1-4,11

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

24 January 2006

Date of mailing of the international search report

08/02/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stolz, B

INTERNATIONAL SEARCH REPORT

PCT/CH2005/000566

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/24417 A (MONASH UNIVERSITY; HERTZOG, PAUL, JOHN; HARDY, MATTHEW, PHILIP; OWCZAR) 4 May 2000 (2000-05-04) claims 17,29 -----	1-3
Y	EP 0 563 487 A (LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE S.A) 6 October 1993 (1993-10-06) page 2, line 35; claim 19 -----	1-3,11
Y	WO 01/36487 A (MILTENYI BIOTECH GMBH; SCHMITZ, JUERGEN; DZIONEK, ANDRZEJ; BUCK, DAVID) 25 May 2001 (2001-05-25) page 10, lines 19-21; claim 152 -----	1-3,11
Y	SCHMID P ET AL: "THE TYPE I INTERFERON SYSTEM IS LOCALLY ACTIVATED IN PSORIATIC LESIONS" JOURNAL OF INTERFERON RESEARCH, MARY ANN LIEBERT, INC., NEW YORK, NY, US, vol. 14, no. 5, October 1994 (1994-10), pages 229-234, XP008017805 ISSN: 0197-8357 cited in the application the whole document -----	1-3,11
Y	WOLLENBERG ET AL.: "Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases" THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 19, no. 5, November 2002 (2002-11), pages 1096-1102, XP002364224 the whole document -----	1-3,11
Y	VAN DER FITS L. ET AL.: "In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered" THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 122, no. 1, January 2004 (2004-01), pages 51-60, XP002364225 cited in the application the whole document -----	1-3,11
P,X	NESTLE F.O.: "Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production" THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 202, no. 1, 4 July 2005 (2005-07-04), pages 135-143, XP002364226 figure 6 -----	1-11

INTERNATIONAL SEARCH REPORT

PCT/CH2005/000566

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 2004067888	A1	08-04-2004	AT AU CA DE EP ES WO JP	291033 T 2865801 A 2397267 A1 60109412 D1 1250358 A1 2240475 T3 0155215 A1 2003525040 T		15-04-2005 07-08-2001 02-08-2001 21-04-2005 23-10-2002 16-10-2005 02-08-2001 26-08-2003
US 2003147889	A1	07-08-2003	AU CA EP WO JP	2865601 A 2401086 A1 1251873 A1 0154721 A1 2003531822 T		07-08-2001 02-08-2001 30-10-2002 02-08-2001 28-10-2003
WO 0154721	A	02-08-2001	AU CA EP JP US	2865601 A 2401086 A1 1251873 A1 2003531822 T 2003147889 A1		07-08-2001 02-08-2001 30-10-2002 28-10-2003 07-08-2003
WO 9828001	A	02-07-1998	AU AU CA EP	730498 B2 5730198 A 2275692 A1 0966300 A1		08-03-2001 17-07-1998 02-07-1998 29-12-1999
WO 0024417	A	04-05-2000		NONE		
EP 0563487	A	06-10-1993	AT AU AU AU BG CA CZ DE DE DK WO ES FI HU JP NO NZ PT US	241008 T 2349697 A 679909 B2 3890793 A 99141 A 2133106 A1 9402369 A3 69332997 D1 69332997 T2 633931 T3 9320187 A1 2199941 T3 944509 A 69995 A2 7505526 T 943625 A 251343 A 633931 T 5919453 A		15-06-2003 24-07-1997 17-07-1997 08-11-1993 28-07-1995 14-10-1993 15-02-1995 26-06-2003 19-05-2004 15-09-2003 14-10-1993 01-03-2004 29-11-1994 28-09-1995 22-06-1995 11-11-1994 27-07-1997 30-09-2003 06-07-1999
WO 0136487	A	25-05-2001	AU CA CN EP JP	1723301 A 2396428 A1 1454215 A 1301539 A2 2004512006 T		30-05-2001 25-05-2001 05-11-2003 16-04-2003 22-04-2004